This study broadens the clinical and molecular spectrum of <i>KCTD17</i>- and <i>KCNN2</i>-related MDS and highlights distinctive features compared with <i>SGCE</i>-MDS, focusing on disease progression, treatment response, and neuropsychiatric involvement. Here, KCNN2 is linked to myelodysplastic syndrome.